Previous studies have identified several transcriptional regulators, including CCAAT‐enhancer‐binding protein beta (C/EBP‐beta), signal transducer and activator of transcription 3 (STAT3), and TAZ, that drive GBM MES differentiation.[11, 12] Therefore, inhibition of these aforementioned regulators may reduce the aggressiveness of MES GBM. This evidence concerns the gene CEBPB and glioblastoma.